Inderal Capsule, Extended Release
FDA Label NDC 62559-523

36 label sections · Submitted to the FDA by Ani Pharmaceuticals, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Ani Pharmaceuticals, Inc. for the product Inderal (NDC 62559-523). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding description, general, mechanism of action, absorption, distribution, metabolism and elimination, enantiomers, special population, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Information For Patients

Inform patients or caregivers that there is a risk of hypoglycemia when Inderal LA is given to patients who are fasting or who are vomiting. Monitor for symptoms of hypoglycemia.

* Please review the disclaimer below.